Applied Therapeutics (APLT) Competitors

Cingulate has higher earnings, but lower revenue than Applied Therapeutics. Cingulate is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Cingulate had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Cingulate and 0 mentions for Applied Therapeutics. Cingulate's average media sentiment score of 1.27 beat Applied Therapeutics' score of 0.00 indicating that Cingulate is being referred to more favorably in the media.

Cingulate has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Applied Therapeutics' return on equity of -340.84% beat Cingulate's return on equity.

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 4.3% of Cingulate shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cingulate currently has a consensus price target of $34.50, indicating a potential upside of 592.77%. Applied Therapeutics has a consensus price target of $1.25, indicating a potential upside of 1,113.59%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Cingulate.

iBio has higher earnings, but lower revenue than Applied Therapeutics. iBio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, iBio had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for iBio and 0 mentions for Applied Therapeutics. iBio's average media sentiment score of 1.66 beat Applied Therapeutics' score of 0.00 indicating that iBio is being referred to more favorably in the media.

iBio has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

iBio's return on equity of -71.26% beat Applied Therapeutics' return on equity.

7.9% of iBio shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

iBio currently has a consensus price target of $4.75, indicating a potential upside of 195.03%. Applied Therapeutics has a consensus price target of $1.25, indicating a potential upside of 1,113.59%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than iBio.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MiNK Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for MiNK Therapeutics and 0 mentions for Applied Therapeutics. MiNK Therapeutics' average media sentiment score of 1.47 beat Applied Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

MiNK Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

MiNK Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 203.29%. Applied Therapeutics has a consensus price target of $1.25, indicating a potential upside of 1,113.59%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than MiNK Therapeutics.

MiNK Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by company insiders. Comparatively, 9.9% of Greenland Mines Ltd. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Greenland Mines Ltd. Common Stock had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.00 beat Greenland Mines Ltd. Common Stock's score of 0.00 indicating that Applied Therapeutics is being referred to more favorably in the media.

Greenland Mines Ltd. Common Stock's return on equity of -137.58% beat Applied Therapeutics' return on equity.

Greenland Mines Ltd. Common Stock has lower revenue, but higher earnings than Applied Therapeutics. Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Applied Therapeutics presently has a consensus price target of $1.25, indicating a potential upside of 1,113.59%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Applied Therapeutics is more favorable than Greenland Mines Ltd. Common Stock.

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Greenland Mines Ltd. Common Stock has a beta of 7.61, suggesting that its share price is 661% more volatile than the S&P 500.